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Highlights 
 
What is already known about the topic? 
 Previous work showed that early intensive treatment in patients with screen detected diabetes is probably not 
cost-effective in the long-term from the UK NHS perspective. 
 However, this initial economic evaluation was based on conservative per protocol assumptions for the 
intervention costs and the incremental costs of the intervention actually delivered to patients might have been 
lower than expected.  
What does the paper add to existing knowledge? 
 By following an iterative approach to research and decision making this study firstly estimates the incremental 
costs of intensive treatment as delivered in the ADDITION trial using electronic primary care records of trial 
participants and secondly updates the long-term cost-effectiveness model according to a previously developed 
evaluation frame. 
What insights does the paper provide for informing health care-related decision making? 
 The updated cost-effectiveness analysis shows that from the UK NHS perspective intensive treatment in 
patients with screen detected diabetes is likely to be cost-effective over a time horizon of 20 years and more.  
Abstract 
Background:  
There is uncertainty about the cost-effectiveness of early intensive treatment vs. routine care in individuals with type 2 
diabetes detected by screening. The aim of this study is to derive a trial-informed estimate of the incremental costs of 
intensive treatment as delivered in the ADDITION trial and to revisit the long-term cost-effectiveness analysis from 
the perspective of the UK National Health Service (NHS).  
Methods:  
We analyzed the electronic primary care records of a subsample of the ADDITION-Cambridge trial cohort (n=173). 
Unit costs of utilized primary care services were taken from the published literature. Incremental annual costs of 
intensive treatment vs. routine care in years 1-5 after diagnosis were calculated using multilevel GLMs. We revisited 
the long-term cost-utility analyses for the ADDITION-UK trial cohort and report results for ADDITION-Cambridge 
using the UKPDS outcomes model and the trial-informed cost estimates according to a previously developed 
evaluation framework.  
Results:  
Incremental annual costs of intensive treatment over years 1-5 averaged £29.10 (SE=£33.00) for consultations with 
GPs and nurses, £54.60 (SE=£28.50) for metabolic and cardio-protective medication. For ADDITION-UK, over the 
10-, 20-, and 30- year time horizon, adjusted incremental quality adjusted life years (QALYs) were 0.014, 0.043, and 
0.048, and adjusted incremental costs were £1,021, £1,217, and £1,311 resulting in incremental cost-effectiveness 
ratios (ICERs) of £71,232/QALY, £28,444/QALY and £27,549/QALY, respectively. Respective ICERs for 
ADDITION-Cambridge were slightly higher.  
Conclusion:  
The incremental costs of intensive treatment as delivered in the ADDITION-Cambridge trial were lower than 
expected. Given UK willingness to pay thresholds in patients with screen detected diabetes intensive treatment is of 
borderline cost-effectiveness over a time horizon of 20 years and more. 
 Background 
Diabetes mellitus is an increasing public health problem, associated with costly micro- and macrovascular 
complications, reduced quality of life, and premature death [1-4]. The direct and indirect societal costs of diabetes in 
the UK are expected to rise from £22bn in 2010 to £35bn in 2030, and a large share of this financial burden is 
attributable to the treatment of diabetic complications in patients with type 2 diabetes [5]. Cost-effective disease 
management strategies are therefore needed to diminish the burden of the disease on patients and health care systems.  
Previous research has shown that intensive multifactorial treatment, including management of cardiovascular risk 
factors and glycemic control, reduces the risk of cardiovascular events and is an effective and cost-effective 
intervention for patients with longstanding diabetes [6-8]. There is also solid evidence that tight control of glucose and 
blood pressure in newly routinely diagnosed patients is an effective and cost-effective strategy [9-11]. Conversely, 
little is known about the cost-effectiveness of intensive treatment in individuals with type 2 diabetes detected by 
screening who, all else being equal, will typically be at an earlier stage in the disease.  
The diagnosis of diabetes in routine care settings occurs on average a couple of years after physiological onset [12]. 
Owing to improvements in quality of care and ongoing considerations about population-based screening, this lead 
time is expected to decrease, resulting in a large number of patients who could potentially benefit from early intensive 
treatment.  
The pragmatic cluster-randomized ADDITION (Anglo-Danish-Dutch Study of Intensive Treatment In People with 
Screen Detected Diabetes in Primary Care–Europe) trial studied the effect of intensive multifactorial treatment 
compared with routine care on cardiovascular morbidity and mortality in individuals with type 2 diabetes detected by 
screening [13, 14]. The results showed a non-statistically significant relative risk reduction in the incidence of the 
composite cardiovascular endpoint over a time horizon of 5 years [15].  
Of note, levels of cardiovascular risk factors improved modestly over the 5 years of the trial, and a modeling study 
using the United Kingdom Prospective Diabetes Study (UKPDS) risk equations indicated that the cardiovascular risk 
might be reduced in the long-term [15, 16]. Despite this, an initial cost-effectiveness analysis using the UKPDS 
outcomes model incorporating conservative protocol-driven intervention cost estimates showed that, over a time 
horizon of 30 years, the intervention was not cost-effective according to current UK willingness to pay (WTP) 
thresholds (ICER~£37,500/QALY vs WTP thresholds of £20,000 to £30,000),[17] albeit with substantial decision 
uncertainty (31% probability that the ICER is below £30,000). However, as we know from a previous study that the 
adherence of General Practitioners (GPs) to the trial protocol was not perfect, the incremental costs of the intervention 
actually delivered might have been lower than expected [18].  Therefore, whilst our outcomes assessment would be 
valid we may have overestimated the incremental cost.  Had the intensive treatment regimen been highly cost-
effective or cost-ineffective and with a high degree of certainty, further exploration would have been of no value.  
However, given the proximity of the ICER to the (upper) threshold and the level of decision uncertainty, we felt 
further investigation into the intervention costs was justified. 
The objective of this study is therefore to estimate the incremental costs of early intensive treatment as delivered in 
ADDITION using empirical data from electronic primary care records. We then use this new information to update 
our prior estimate of the long-term (10-30 years) cost-effectiveness analysis of the ADDITION intervention in the UK 
from an NHS perspective, in a manner consistent with an iterative approach to research and decision making [19-21]. 
Methods 
Study design and study population 
The ADDITION-UK (NCT00237549) study is part of the ADDITION-Europe study and consisted of two phases– a 
screening program and a pragmatic, cluster-randomized trial comparing the effect of early intensive treatment vs. 
routine care in individuals with type 2 diabetes detected by screening on a composite endpoint of cardiovascular 
morbidity and mortality [13, 14]. High risk individuals without known diabetes aged 40-69 years registered in 69 
primary care surgeries within a range of 100 miles of the study centers in Cambridge and Leicester were invited to 
stepwise screening. Some 867 individuals (from 49 surgeries) from Cambridge and 159 individuals (from 20 
surgeries) from Leicester with type 2 diabetes detected by screening participated in the primary care-based 
intervention study (ADDITION-UK). Two participants withdrew before year 5, leaving a total study size of 1024 
participants. Details of the study protocol including assessment of primary endpoints and in- and exclusion criteria 
have been published elsewhere [15]. The study was approved by local ethics committees, and all participants provided 
informed consent. 
Routine care vs. intensive treatment 
Patients were treated according to the treatment allocation of their surgery. Patients in the routine care arm in Leicester 
and Cambridge received diabetes care through the UK National Health Service (NHS) based on contemporary UK 
treatment guidelines [22-24]. In the intensive treatment arm, additional features were added to routine care. Some of 
these intensive treatment features differed between the Leicester and Cambridge GP surgeries.  
In Leicester, intensive treatment was delivered by a specialist team of doctors, nurses, and dieticians within peripatetic 
community clinics according to the Diabetes Education and Self-Management Programme (DESMOND). DESMOND 
is a group education program delivered by two registered health care professionals in one 6-hour session [25]. The 
curriculum focuses on lifestyle changes and medication adherence using theories of efficient goal setting and self-
efficacy. Additionally, in the first year after diagnosis, patients were offered bi-monthly appointments with a nurse or 
a GP in a community peripatetic clinic, and 4-monthly thereafter. 
In Cambridge, primary care surgeries received funding for more frequent contacts between patients and practitioners. 
An initial practice-based academic detailing session conducted by a local diabetologist and an academic GP and 
interactive practice-based audit and feedback sessions were organized around 6 and 14 months after the initial 
education session and annually thereafter. Surgery staff received theory-based education materials to hand over to 
patients, and participants were encouraged to initiate lifestyle changes, to adhere to medication schemes, to self-
monitor blood glucose levels if given a glucometer by their practice, and to attend annual health checks. 
Additionally, in all intensive treatment arm surgeries (Leicester and Cambridge) GPs were advised to follow treatment 
algorithms for medication with glucose lowering, angiotensin converting enzyme (ACE) inhibiting, lipid lowering, 
and platelet inhibiting medication that were slightly tighter than those in contemporary UK treatment guidelines [13, 
22-24]. According to the protocol, therapy with glucose lowering medication was indicated for patients with an 
HbA1c >6.5%, therapy with ACE inhibitors for patients with blood pressure >120/80 mmHg or prevalent CVD, statin 
therapy for patients with a cholesterol level>3.5 mmol/L, and aspirin therapy for all patients without specific 
contraindications [14]. 
Incremental costs of intensive treatment in ADDITION-Cambridge 
Data source and operationalization 
Due to the high cost of assessing and extracting data from electronic primary care records it was decided in the 
planning phase of the study that only the records of a subset of the study would be assessed. Records of each 
participant with a primary endpoint (i.e. CV event) plus the records of two random participants from the same GP 
surgery without a primary endpoint within the 5 year trial period were accessed. Consequently, the records of 30 
participants with a primary endpoint and of 60 participants without a primary endpoint from the intensive treatment 
arm and the records of 33 participants with a primary endpoint and of 66 participants without a primary endpoint from 
the routine care arm were accessed.  
These records comprised information on consultations with outpatient health care professionals, prescribed 
medications, and diagnostic tests from the date of diagnosis (between 2002 and 2005) until the end of the year 2010 (~ 
80,000 observations in total). Costs associated with the utilization of these services were obtained by multiplying the 
number of consumed resources by their respective unit prices. Unit prices for consultations with GPs and nurses were 
extracted from the Personal Social Services Research Unit (PSSRU) report on Unit costs of Health and Social Care 
[26]. Prices for all other consultations were taken from the National Schedule of Reference Costs 2009-10 for NHS 
Trusts [27]. The Prescription Cost Analysis (PCA) 2010 was used to assign unit prices for prescribed medications 
[28]. Owing to incomplete or ambiguous information from the free-text records, no unit costs could be assigned to 
around 1% of the recorded utilized resources. These services were therefore priced according to the mean unit price of 
utilized units for this person and year.  
Based on the study protocol, we allocated cost items to the following categories: 
(i) costs for consultations related to the trial protocol (contacts with GPs and nurses); 
(ii) costs for medication related to the trial protocol (glucose lowering drugs, blood pressure lowering drugs, 
cholesterol lowering drugs, platelet inhibiting drugs);  
(iii) costs for all other services (contacts with other primary health care professionals and outpatient specialists, other 
medications, and diagnostic tests). 
Statistical analyses 
In the long-term decision model costs for primary care and medication accrue until a person dies. As input parameters 
for this decision model one therefore needs an empirical estimate that describes the difference in average costs 
between a person alive in the intensive treatment arm and a person alive in the routine care arm. For this, we 
subdivided the 5-year analysis period into five annual intervals (year 1 to year 5 after diagnosis) and included the 
observation year in which a person died, but excluded subsequent years from the analysis. After exclusion of 16 
participants for whom none or less than one year’s data were available, 173 participants (from 34 surgeries, mean 
cluster size=5; min=2, max=17) provided 841 person years of data until death. Medication data were missing for 18 of 
the 173. These costs were imputed with Markov Chain Monte Carlo procedures using model covariates and available 
annual cost values for consultations, medications, and diagnostic tests. This yielded a final analysis sample of 173 
participants with 841 complete observation years.  
Here we firstly descriptively report the resource utilization of categories (i) and (ii) which has been described in detail 
elsewhere [18]. Secondly, we analyzed the annual incremental costs of intensive treatment for each resource 
utilization category separately using generalized linear models (GLMs). We tested a GLM with identity-link and 
Gaussian distribution (i.e. OLS-model), a GLM with log-link and gamma/Poisson distribution and a GLM with square 
root link and gamma/Poisson distribution (in models with a log-link all zero costs were set to a nominal £1)[29]. 
Results from these models were very similar; for overall costs we decided to use the OLS model which is the simplest 
and yielded the most conservative cost estimates [30]. Models accounted for observation years being clustered into 
patients and patients being clustered into primary care surgeries (three-level random intercept model) and were 
adjusted for age, sex, and HbA1c at diagnosis. We also introduced an interaction term between the year after diagnosis 
and the treatment status to capture potential trends over time. In a second step, using the same statistical methods, we 
estimated the total annual incremental costs. To account for the non-random selection of the analyzed subsample, we 
introduced a general weighting factor, representing the inverse probability of being included in this analysis, based on 
the status of having a primary endpoint [31]. 
These models yielded mean estimates and SEs for the annual incremental costs of consultations (βconsultations-Cambridge; 
SEconsultations-Cambridge), medication (βmedication-Cambridge; SEmedication-Cambridge), and the intervention as a whole, including other 
primary care services (βtotal-Cambridge; SEtotal-Cambridge). Analyses were performed with SAS 9.3 using the GLIMMIX, MI, 
and MIANALYZE procedures (Cary, NC, USA). 
Long-term cost-effectiveness of intensive treatment in ADDITION-UK/Cambridge 
The long-term cost-effectiveness of ADDITION used the outputs from the UKPDS model as per the original model, 
with the updated short-term intervention costs from the electronic primary care records.  The methods are briefly 
described below.  The analysis is conducted from the perspective of the NHS.  As we only have empirical data on the 
intervention costs from the Cambridge centers but not from the Leicester centers we firstly update the previous cost-
effectiveness analyses for ADDITION UK (Leicester and Cambridge). In a second step we report a separate long-term 
cost-effectiveness analyses for ADDITION-Cambridge, only.  
QALYs 
The UKPDS outcomes model v1.3 was applied to simulate the individual accumulated QALYs of patients [17, 32]. 
The UKPDS outcomes model is a widely used individual-level state transition simulation model a micro-simulation 
model based on data from a UK population and applicable for the given evaluation context [33]. Its performance has 
been tested against the ADDITION 5-year outcomes in a previous study showing a moderate calibration and 
discrimination [34]. The model predicts future events (ischemic heart disease, myocardial infarction, heart failure, 
stroke, amputation, blindness, renal failure) and death as a function of several values at diagnosis of diabetes (e.g., sex, 
ethnicity, duration of diabetes) and based on values of risk factors at diagnosis and in subsequent years (e.g., smoking, 
body mass index (BMI), cholesterol, high-density lipoprotein (HDL), HbA1c, systolic BP). Results on risk factor 
changes and effects on micro and macrovascular events over the 5 year observation period have been reported 
previously and are summarized in Appendix 1 [15-17, 35]. Utility decrements associated with the modeled events 
were obtained from the published literature, and the additive method was used for patients with multiple events 
(Appendix 2) [36-38]. 
Costs 
We assumed that the costs for patients in the intensive treatment arm comprise the costs of treatment of complications 
plus the costs of the delivering the intervention itself, including costs for planning and implementation and for extra 
consultations and medication, whereas in the routine care arm, only the costs of the treatment of complications occur. 
All costs were calculated in British pounds (GBP) for the price year 2009/2010. The price year was chosen to maintain 
comparability with the previous economic analysis [17]. 
Treatment of events/complications: As for the effects, we used the UKPDS outcomes model v1.3 to estimate the per 
patient (pp) costs for treatment of events and complications [32]. Unit costs for the treatment of complications were 
obtained from the UKPDS study and other published literature (Appendix 2 [37-39]. Again, the additive method was 
used to calculate costs in case of multiple complications or events. 
Planning and implementation: The previously published internal accounting showed average pp costs of £375 in 
Cambridge and £71 in Leicester for the planning and implementation (teaching and feedback sessions) of the study 
[17]. Those values were also used in this analysis.  
Extra consultations and medication: For Cambridge (total n=867), we used the empirically derived cost estimates 
(βconsultations-Cambridge, SEconsultations-Cambridge, βmedication-Cambridge, SEmedication-Cambridge). For Leicester (total n=159), no empirical 
cost data were available, and we used the cost estimates from the internal accounting[17], which were used for the 
protocol-based cost-effectiveness analysis [17]: βconsultations-Leicester (annual pp costs for extra consultations in years 1-
5)=£880/5=£176 and βmedication-Leicetser (annual pp costs for extra medication in years 1-5 and thereafter)=£52.5. A 
detailed description of the protocol-based cost estimates is provided in Table 1. 
Statistical analysis  
For patients in both trial arms, the individual 10-, 20-, and 30-year accumulated QALYs and costs for the treatment of 
complications were projected by running simulations with 1,000 inner model loops and 100 bootstraps of the UKPDS 
outcomes model v.1.3 with a cycle length of one year [32]. Both costs and QALYs were discounted at a rate of 3.5% 
according to the guidelines of the National Institute for Health and Care Excellence (NICE) [40]. Some minor 
adjustments to the input data were performed before running the model: Patients with unknown or unclassifiable 
ethnicity were excluded from the analysis (n=25), and values of atrial fibrillation, peripheral vascular disease, 
ischemic heart disease, congestive heart failure, amputation, blindness, and renal failure, which were not collected in 
ADDITION, were set to zero. Further, missing values of input variables were imputed via MCMC procedures (n=5 
imputations), and means and SEs were subsequently derived using Rubin’s rules (supplementary information on the 
missing data is provided in Appendix 3).  
As a base case scenario, we calculated the incremental cost-effectiveness for ADDITION-UK, including patients from 
Cambridge and Leicester. To the simulated costs for the treatment of complications which occur in both treatment 
arms, for patients in the intervention arm, we added the per patient (pp)  mean costs for planning and implementation 
of the intervention, the discounted pp mean costs for extra consultations in years 1-5 , and the 
discounted pp mean costs for medication until death ). Life expectancy (LE) for the 10-, 20-, and 
30- year time horizons averaged ~9, ~15, and ~17 years. SEs of the different cost components were summed in an 
additive manner. In parallel to the method described by Tao et al. 2015, the resulting means and SEs of QALYs and 
costs at patient level were used to conduct a bootstrap analysis (n=500) adjusting for center, age at diagnosis, gender, 
and HbA1c at baseline [17].  
We report the ICERs for the 10-, 20-, and 30-year time horizons and the probability of the intervention being cost-
effective given a WTP threshold of £30,000. We also illustrate the decision uncertainty with a scatterplot in the cost-
effectiveness plane and a cost-effectiveness acceptability curve. In additional analyses, we assumed that not only the 
costs of medication were incurred until death, but that the total incremental primary care costs, including costs of 
consultations and other primary care services, were incurred until death .  
Analyses of modeled scenarios were conducted using the UKPDS outcomes v1.3 model and Microsoft Excel 
(Redmond, WA, USA). The manuscript was composed according to the Consolidated Health Economic Evaluation 
Reporting Standards (CHEERS) statement [41]. 
Sensitivity analysis: We estimated an alternative model in which we incorporated total incremental primary care costs, 
including costs of consultations and other primary care services.  
One-way sensitivity analyses were performed on the main model for ADDITION UK with varying treatment costs, 
utility decrements, and discount rates using the 30-year simulation data. The range for the discount rate (0%, 5%) was 
guided by NICE guidelines suggesting a discount rate of 3.5% as base case and 1.5% in sensitivity analyses [42]. The 
range for utility decrements and unit costs (-20%, +20%) was guided by the coefficient of variation of parameter 
estimates which averaged approximately 8-12% in the data sources from which the input parameters were taken [36, 
39]. 
We also adjusted our models to most recently available prices as relative prices, particularly for medications, might 
have changed substantially since 2010. The PSSRU Unit Costs of Health and Social Care 2010 and 2015 [43, 44], the 
British National Formulary (BNF) for 2010 and 2016 [45], and the NHS trust reference cost schedules (NSRC) for 
2009/2010 and 2015/2016 [46, 47] were used to retrieve relative price changes for GP and nurse contacts, for cardio-
metabolic medications, and for  hospitalizations of diabetes-related complications (compare Appendix 4). 
Results 
Study design and study population 
Baseline characteristics of the total UK sample and of the weighted Cambridge subsample are presented in Table 2. 
The mean age of the UK sample was around 61.5 years. No substantial differences were observed between the UK 
sample (n=1024) and the weighted Cambridge subsample from which empirical cost data were available (n=173).  
Incremental costs in ADDITION-Cambridge 
The primary care cost components for patients in the intensive treatment and routine care arm are illustrated in Figure 
1. Respective resource utilization for contact with health care professionals and medication related to the trial protocol 
is illustrated in Appendix 5. The majority of costs are attributable to contacts with GPs, metabolic and cardio-
protective medication and other types of medications. The annual costs for contacts with GPs, nurses, and other health 
care professionals (HCP) and the annual costs for glucose lowering drugs, BP lowering drugs, lipid lowering drugs, 
aspirin, other medication, and diagnostic tests stayed constant or increased over the 5-year time horizon. Significant 
cost differences between the intensive treatment arm and the routine care arm were only observed for glucose 
lowering and lipid lowering drugs.  
The mean incremental annual costs of intensive treatment are illustrated in Table 3. Total incremental annual costs pp 
over the 5-year time period averaged £92 (βtotal-Cambridge=92.0, SEtotal-Cambridge=115.4) using a GLM with a Gaussian 
distribution and an identity link. Incremental annual costs pp for GP/nurse consultations, and for metabolic/cardio-
protective medication averaged £29 (βconsultation-Cambridges=29.1, SEconsultations-Cambridge=33.0) and £55 (βmedication-Cambridge= 
54.6, SEmedication-Cambridge=28.5), respectively. The incremental costs for other services were £6 (β=5.7, SE=89.1). 
Around 5% of the variation in the total incremental costs was explained by the clustering of patients into surgeries 
(intra-class correlation coefficient (ICC)=0.036). A detailed analysis of the cost pattern over time showed that the cost 
difference varied considerably between the observation years (Appendix 6). Omitting the weighting factor or 
performing a complete case analysis (without imputed observation years) altered the results only marginally.  
Long-term cost-effectiveness in ADDITION-UK 
Table 4 shows the crude accumulated QALYs and costs over the 10-, 20-, and 30-year time horizon for ADDITION-
UK and ADDITION Cambridge. Table 5 shows the adjusted incremental QALYs, costs and ICERs for ADDITION-
UK and ADDITION-Cambridge. Due to larger cardiovascular risk factor reductions in Leicester [16, 35] incremental 
QALYs in ADDITION-UK were higher than in ADDITION-Cambridge. However, due to higher implementation 
costs in Leicester (βconsultation), incremental costs in ADDITION-UK were higher than in ADDITION-Cambridge. 
Resulting ICER point estimates for the 10, 20 and 30 year time horizon were £71,232/QALY, £28,444/QALY and 
£27,549/QALY for ADDITION-UK, and £96,570/QALY, £36,115/QALY, £29,588/QALY for ADDITION-
Cambridge. 
Figure 2 shows the scatterplot of the 10-, 20-, and 30-year QALY and cost pairs of bootstrap replications in the cost-
effectiveness plane and the cost-effectiveness acceptability curve. For all three time horizons, the majority of points lie 
in the north-east quadrant. For ADDITION-UK 0.7%, 53.5%, and 56.0% and for ADDITION-Cambridge 0.9%, 
39.5% and 50.0%.are positioned below the £30,000/QALY WTP threshold.  
Sensitivity analyses: Incorporating total incremental primary care costs, including costs of consultations and other 
primary care services yielded a 30-year ICER point estimate of £33k/QALY for ADDITION-UK and of £38k/QALY 
for ADDITION UK. The one-way sensitivity analysis with varying unit costs, discount rates, and utility decrement for 
ADDITON-UK is illustrated in the tornado diagram of Figure 3. It shows that for the specified ranges the ICER point 
estimate for ADDITION-UK lies close to or below the threshold of £30,000/QALY. Results from the sensitivity 
analysis for ADDITION-Cambridge are similar (not shown). Between 2010 and 2015/16, relative prices increased by 
44% for GP and nurse contacts, by 15% for unit costs for treatment of diabetes complications, and decreased by 41% 
for relevant cardio-metabolic medications (Appendix 4). The price change adjusted models resulted in ICERs of 
£25k/QALY for ADDITION UK and £27k/QALY for ADDITION-Cambridge.    
Discussion 
Summary 
There is uncertainty about the costs and the cost-effectiveness of early intensive multifactorial treatment as delivered 
in the ADDITION trial. Based on electronic primary care records of a subsample of the trial cohort, we analyzed the 
incremental costs of delivered intensive treatment in ADDITION-Cambridge. Following an iterative framework of 
decision making in health care, we used these empirical cost estimates to update the previously published cost-
effectiveness analysis for ADDITION-UK and present estimates for ADDITION-Cambridge. The results show that 
the intervention was delivered at lower costs than previously assumed and that there is a moderate likelihood that the 
intervention will be cost-effective over a time horizon of 30 years. 
Discussion of results 
The difficulty of decision making in the context of chronic diseases is that potential positive effects of treatment, i.e., 
reduction in cardiovascular events and premature death, are likely to occur far from the time when interventions are 
delivered to patients. This issue is of particularly high relevance for interventions that target populations at a very 
early stage in disease progression, as in the case of treatment for individuals with type 2 diabetes detected by 
screening. As decisions in health care often need to be made promptly and cannot be postponed until evidence from 
long-term trials is available, models that simulate the natural course of the disease, and with it the expected effects 
(QALYs) and costs, have been established as helpful tools [48]. However, simulation models rely on a set of 
assumptions and input parameters that crucially determine the results of the simulation.  
To assess the cost-effectiveness of the ADDITION intervention, we previously used the UKPDS outcomes model, 
which projects accumulated QALYs and costs over a 10-, 20-, and 30-year time horizon. This analysis showed that 
ICERs were only moderately sensitive to the used input parameters (unit costs for treatment of events, utility 
decrements for events, discount rate), but highly sensitive to the assumptions on the costs of the intervention itself 
[17]. The input parameter for the incremental treatment costs was solely estimated on the trial protocol assuming 
100% protocol adherence. To receive an empirical, trial-informed estimate, we therefore analyzed the electronic 
primary care records of a subset of the ADDITION-Cambridge trial cohort and used this data to update the long-term 
cost-effectiveness model.  
The results of the empirical analysis show that the incremental pp costs for actually delivered consultations were lower 
than expected (£145 empirical vs. £311 protocol-based for years 1-5), but that the assumption for extra medication 
was appropriate (£54.6 empirical vs. £52.5 protocol- based annually, compare Table 1). The former suggests that GPs 
did see their patients more often, but not to the extent for which they were reimbursed within the trial. The latter 
indicates that incremental costs for medication actually delivered were as high as the per-protocol estimated costs, 
which were based on the assumption of 100% protocol adherence with generic drug agents. This is surprising, as we 
know that the protocol adherence was not perfect [18]. A possible explanation for this finding is that the reduction of 
costs resulting from the suboptimal medication adherence has been cancelled out by an increase of costs resulting 
from the high usage of non-generic drugs observed in both treatment arms. In more detailed analyses, for example, we 
observed that after the year 2003 when simvastatin went off patent more than 35% of statin prescriptions were still for 
the much more expensive atorvastatin. Of note, costs for primary care services which were not directly related to the 
trial protocol were almost equal in both trial arms.  
Revisiting the previously developed robust evaluation framework [17] with the empirical trial-informed cost estimates 
shows that the intervention has a moderate likelihood of being cost-effective over a time horizon of 30 years, 
assuming the higher UK NICE WTP threshold of £30,000/QALY. Our sensitivity analyses also indicated that the 
intervention might be cost-effective with most recent prices. 
This study also shows that empirical information on the incremental costs of the delivered intervention is invaluable 
for the economic evaluation of this trial. Unknown protocol adherence and the magnitude of generic drug usage can 
lead to a considerable over- or underestimation of incremental costs. Trialists should consider whether there could be 
value in measuring adherence to protocol when designing future pragmatic studies. 
Comparison with the initial cost-effectiveness analysis 
The cost-effectiveness analysis in this study is based on a previously developed modeling framework [17]. However, a 
few minor methodological adaptations have been made. Supported by the empirical data annual costs for extra 
consultations in ADDITION-Cambridge were assumed to occur until year 5 and not only until year 3. Further, the 
uncertainty of incremental costs was considered in the cost-effectiveness model by incorporating the standard errors of 
the empirically derived incremental cost estimates in an additive manner. In the initial long-term cost-effectiveness 
analysis we also erroneously presumed that the mean costs for additional medication would be incurred until the end 
of the 10-, 20-, and 30-year simulation time horizon independently of individual simulated deaths of participants [17]. 
In this study, we took the more plausible assumption that costs for extra medication will occur until a person dies or 
reaches the end of the simulated time horizon. Applying this assumption to the previous cost-effectiveness analyses 
would have led to ICER point estimates of around £83k/QALY, £32k/QALY, and £30k/QALY for a 10-, 20-, and 30-
year simulation time horizon. The decrease of the ICER in our study can be explained by the lower frequency of extra 
consultations compared to the per-protocol assumed costs in the ADDITION-Cambridge sample (compare Table 1).  
Strengths and limitations 
The main strength of this study is the use of empirical data from electronic primary care records from a subsample of 
the ADDITION-Cambridge trial sample. The use of these data provided a unique insight into the cost structure of 
intensive treatment as delivered in the ADDITION trial and allowed us to perform a detailed analysis of incremental 
cost components. This allowed us to revisit the cost-effectiveness analyses with the updated cost estimates using a 
previously developed robust evaluation framework and incorporated the uncertainty around the empirically derived 
cost estimates.  
There are also some limitations that need to be taken into account. First and most importantly, the risk equations of the 
UKPDS outcomes model v1.3 were derived from an historical cohort followed from 1977 to 1997. As the general 
quality of diabetes care has improved since then, the model overestimates the absolute CVD risk in current 
populations. This finding was replicated in a previous validation study based on ADDITION data. However, this 
validation study also showed that the model performed reasonably well in the prediction of incremental cardiovascular 
event rates in the ADDITION-UK sample [34]. Second, the input parameters for costs and utility decrements 
associated with the modeled events might be outdated und updating for inflation will not account for changes in 
relative prices. We therefore performed sensitivity analyses on these parameters, which showed that the results were 
only moderately sensitive towards variation in these parameters. Third, we only had empirical information on primary 
care costs for around 20% of the ADDITION-Cambridge trial cohort. We therefore kept the protocol-based 
assumptions for participants from Leicester in the analysis for ADDITION-UK, but performed separate analyses 
restricted to ADDITION-Cambridge participants. We further assigned mean cost estimates instead of individual-level 
costs to patients from Cambridge and Leicester. Fourth, owing to the relatively small sample size, the clustering of 
patients into GP practices, and the non-availability of information on resource utilization before randomization the 
uncertainty around the cost estimates remained relatively large. Fifth, we only had empirical information on primary 
care contacts. We therefore used the risk factor profile of participants together with the UKPDS Outcomes Model to 
predict complications and costs, (including hospital costs) associated with those complications. However, we do not 
know if the intervention provoked or prevented other unexpected care use that is not captured by the model and also 
not by our empirical primary care cost analyses. This shortcoming could have biased the cost estimates and ICERs in 
either direction. Sixth, we estimated incremental costs for medication based on prescriptions issued. However, we do 
not know how many of these were actually dispensed and we therefore probably overestimated the absolute (and 
incremental) costs for medications. Other limitations, such as the fact that the UKPDS outcomes model does not 
incorporate all diabetes-related complications and that the ADDITION-UK sample does not adequately represent UK 
ethnic diversity, limiting its external validity, have been discussed in detail by Tao et al. [17].  
Conclusion 
Revisiting and correcting the initial cost-effectiveness analyses with empirical trial-informed cost estimates suggests 
that money spent on intensive treatment in individuals with type 2 diabetes detected by screening might be borderline 
cost-effective according to conventional UK WTP thresholds. However, the results need to be interpreted with caution 
as the projection of trial data over a long time horizon is almost always associated with substantial uncertainty. 
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 Figures  
Figure 1:  
Title: 
Adjusted means of annual primary care costs according to Intensive Treatment (gray) and Routine Care (black) in 
years 1-5 
# 
Legend: 
# generalized linear model (gamma distribution and log link) with a main effect for the intervention and for time since 
diagnosis and an interaction term between intervention and time; adjusted for sex and age of diagnosis and baseline 
HbA1c; accounted for patients being clustered in GP surgeries and observations clustered in patients; HCP health care 
professionals; Owing to the choice of the family distribution no SE is available for the cost difference. 
 
Figure 2:  
Title: 
Cost-effectiveness plane showing pairs of incremental costs and QALYs and cost-effectiveness acceptability curve 
showing the probability of intensive treatment being cost-effective 
Legend: 
Cost-effectiveness plane showing pairs of 10, 20, and 30 years incremental cost and QALYs from bootstrap samples; 
Cost-effectiveness acceptability curves which show the probability of intensive treatment being more cost-effective 
than routine care based on net benefit values from bootstrap samples over a time horizon of 10, 20, and 30 years 
 
Figure 3: 
Title:  
Tornado diagram showing the influence of changing different parameters 
Legend: 
Tornado diagram showing the influence of changing different parameters that contribute to the ICER in long-term 
cost-effectiveness modelling analysis. Choice of discount rate has the greatest impact on the ICER (higher discount 
rate, unit costs and lower utility decrements all associated with higher point estimate ICER). 
 
 

Tables 
Table 1: Protocol-based and empirical cost estimates used in the initial [17] and updated base-case cost-effectiveness analysis 
Cost component Center 
per protocol 
1
 trial-based 
2 
 
accumulated  annually accumulated  annually 
mean SE mean SE mean  SE  mean  SE 
  upfront costs 
Costs ‘planning and implementation’ 
Cambridge (n=452) 375.1 - - - 375.1 0.0 - - 
Leicester (n=61) 71.2 - - - 71.2 0.0 - - 
  year 1-5 
˫
 
Costs 'Extra Consultations'  
Cambridge (n=452) 311.3
#
 - 62.3
##
 - 145.5 161.5 29.1 
c
 32.3 
d
 
Leicester (n=61) 880.1
#
 - 176.0
##
 - 880.1 976.9* 176.0 195.4 * 
Costs 'Extra Medication'  
Cambridge (n=452) 262.5 - 52.5 - 273.0 142.5 54.6 
e
 28.5 
f
 
Leicester (n=61) 262.5 - 52.5 - 262.5 137.0* 52.5 27.4 * 
  Year 6 until … 
  
end of observation period death or end of observation period 
Costs 'Extra Medication' (year 6-10) 
Cambridge  (n=452) 199.6 ¬ - 52.5 -     183.7 ˨ 95.9 54.6 28.5 
Leicester (n=61) 199.6 ¬ - 52.5 -     203.4 ˨ 106.2* 52.5 27.4 * 
Costs 'Extra Medication' (year 6-20) 
Cambridge  (n=452) 509.1 ¬ - 52.5 -     386.9 ˨ 201.9 54.6 28.5 
Leicester (n=61) 509.1 ¬ - 52.5 -     434.9 ˨ 227.0* 52.5 27.4 * 
Costs 'Extra Medication' (year 6-30) 
Cambridge  (n=452) 728.5 ¬ - 52.5 -     444.3 ˨ 231.9 54.6 28.5 
Leicester (n=61) 728.5 ¬ - 52.5 -     520.3 ˨ 271.6* 52.5 27.4 * 
1) protocol-based cost estimates according to the internal accounting of Tao et al. 2015 [17] 
2) empirical cost estimates according to the analysis on a subsample of the ADDITION sample; 
c - f)  ßs and SEs extracted from Table 2; 
˫
 accumulated costs described without discounting 
* SE in Leicester were assumed to be proportional to the ones in patients from Cambridge; 
# costs were assumed to occur from year 1-3 
##  annual costs if distributed over 5 years 
 
¬ calculated through     
 
˨ calculated through    ,   
Modeled life expectancy (LE) for the 10-, 20-, and  30- year time horizons averaged ~9.4, ~15.2, and ~17.0 years in Cambridge and  ~9.6, ~16.3 and ~19.3 years in Leicester 
 
 Table 2: Baseline characteristics of the ADDITION population trial cohort 
  
ADDITION-UK  
(Cambridge + Leicester) 
ADDITION-Cambridge 
subsample (weighted*) 
IT RC IT RC 
N
 #
 513 511 82 91 
Primary outcome [%] 7.2 7.5 6.8 7.7 
Female sex, [%] 36.6 40.7 40.8 39.4 
Mean age (SD), [years] 61.1 (7.2) 60.1 (7.5) 61.8 (7.3) 61 (7.1) 
Mean BMI (SD), [kg/m
2
] 33.1 (5.6) 33.0(5.9) 33.4 (5.2) 34 (5.7) 
Mean total cholesterol (SD),  [mmol/L] 5.3 (1.1) 5.5 (1.2) 5.4 (1.1) 5.6 (1.2) 
Mean HDL (SD), [mmol/L] 1.17 (0.4) 1.2 (0.3) 1.2 (0.3) 1.2 (0.3) 
Mean systolic blood pressure (SD),  [mmHg] 142.0 (20.1) 143.1(19.4) 141.6 (21) 142.5 (20.6) 
Mean HbA1c (SD), [%] 7.3 (1.7) 7.3 (1.7) 7.7 (2.2) 7.4 (1.7) 
SD, Standard Deviation; BMI, Body Mass Index; HDL, High Density Lipoprotein; HbA1c, glycated hemoglobin;  
* weighting factor: inverse probability of being included in the study based on the status of having a primary endpoint 
RC, routine care; IT, intensive treatment; # n=2 of the total sample (n=1026) withdrew from the study 
 
 
Table 3: Adjusted means of annual primary care costs according to Intensive Treatment and Routine Care in the years 1-5 # 
  
Total  
Consultations 
(ADDITION)  
Medication     
(ADDITION)  
Other primary care 
services 
  mean  (SE) mean  (SE) mean  (SE) mean  (SE) 
Generalized linear model with Gaussian distribution and identity link 
IT 906.3 (82.2) 266.4 (23.2) 182.1 (19.9) 454.1 (63.8) 
RC 814.3 (81) 237.2 (23.5) 127.6 (20.4) 448.3 (62.3) 
Difference 92
a
 (115.4)
b
 29.1
c
 (33)
d
 54.6
e
 (28.5)
f
 5.7 (89.1) 
# generalized linear regression models with a main effect for the intervention and for time since diagnosis and an interaction term between intervention 
and time; adjusted for sex and age of diagnosis and baseline HbA1c; accounted for patients being clustered in GP surgeries and observations clustered in 
patients, model based on 841 observation years from 173 patients 
estimates used for long-term CE-model: 
a
 ß total ; 
b
 SE total ;  
c
 ß consultation ; 
 d
 SE consultation ; 
e
 ß medication ;  
f
 SE medication 
 Table 4: Crude Cumulative cost and QALYS according to Intensive Treatment (IT) and Routine Care (RC) 
 
ADDITION-UK (Leicester & Cambridge) 
  Routine Care Intensive Treatment 
    crude costs crude QALYs   crude costs crude QALYs 
Time 
Horizon 
n mean  (SE) mean  (SE) n mean (SE) mean (SE) 
10 years 501 6,157 (332) 6.45 (0.08) 498 7,256 (879) 6.40 (0.09) 
20 years 501 11,175 (867) 9.32 (0.21) 498 12,392 (1,614) 9.16 (0.23) 
30 years 501 13,181 (1,325) 10.08 (0.30) 498 14,308 (2,110) 9.82 (0.31) 
ADDITION-Cambridge 
 
Routine Care Intensive Treatment 
  
crude costs crude QALYs 
 
crude costs crude QALYs 
Time 
Horizon 
n mean (SE) mean (SE) n mean SE mean (SE) 
10 years 501 6,228 (341) 6.42 (0.08) 498 7199 772,65 6.39 (0.09) 
20 years 501 11,208 (885) 9.21 (0.22) 498 12291 1496,87 9.11 (0.23) 
30 years 501 13,102 (1,324) 9.89 (0.31) 498 14170 1979,61 9.76 (0.31) 
 
 
Table 5: Adjusted incremental costs and QALYs and incremental cost-effectiveness ratios (ICER) 
# 
 
ADDITION-UK (Leicester & Cambridge) 
Time 
Horizon 
Adjusted incremental 
Cost (95% CIs) 
Adjusted incremental 
QALYs (95% CIs) 
ICER P(ICER<£30,000/QALY)* 
10 years 1,021 (920, 1,120) 0.0143 (-0.0015, 0.0294) 71,232 0.007 
20 years 1,217 (1,029, 1,406) 0.0428 (0.0034, 0.0817) 28,444 0.535 
30 years 1,311 (1,072, 1,559) 0.0476 (0.0011, 0.0932) 27,549 0.560 
ADDITION-Cambridge  
Time 
Horizon 
Adjusted incremental 
Cost (95% CIs) 
Adjusted incremental 
QALYs (95% CIs) 
ICER P(ICER<£30,000/QALY)* 
10 years 927 (831, 1,017) 0.0096 (-0.0079, 0.0267) 96,570 0.009 
20 years 1,086 (909, 1,268) 0.0301 (-0.0144, 0.0708) 36,115 0.395 
30 years 1,157 (908, 1,414) 0.0391 (-0.0107, 0.0892) 29,588 0.500 
# means and SE of QALYs and costs at patient level were used to conduct a bootstrap analysis (n=500) adjusting for center, age at diagnosis, 
gender, and HbA1c at baseline 
* probability that the ICER is below £30,000/QALY 
 
   
 
 
 
Appendices 
Appendix 1a: Baseline and five-year follow-up values for clinical variables for ADDITION-UK* 
 Routine Care Intensive treatment 
Adjusted difference* (SE) 
(follow up-baseline) 
Adjusted difference* (SE) 
(follow up-baseline) 
HbA1c (%) –0.25 (0.09) –0.37 (0.09) 
Total cholesterol (mmol/l) –1.20 (0.07) –1.30 (0.06) 
Systolic blood pressure (mmHg) –7.08 (1.13) –7.32 (1.18) 
* 85% of patients from are ADDITION UK belong to ADDITION Cambridge, compare Tao, L., et al. (2015). "Cost-effectiveness of intensive multifactorial 
treatment compared with routine care for individuals with screen-detected Type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial." 
Diabet Med 6(10): 12711. 
Appendix 1b: Hazard ratios for primary and secondary cardiovascular outcomes for ADDITION-UK* 
 
Routine Care Intensive treatment 
HR (95%-CI) 
Myocardial infarction ref 1.08 (0.40–2.94) 
Stroke ref 1.11 (0.52–2.35) 
Revascularization ref 0.68 (0.32–1.46) 
CVD death ref 0.45 (0.19–1.06) 
All-cause death ref 0.59 (0.35–0.98) 
Composite cardiovascular events ref 0.80 (0.55–1.17) 
* 85% of patients from are ADDITION UK belong to ADDITION Cambridge, compare Griffin, S. J., et al. (2011). "Effect of early intensive multifactorial therapy 
on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial." Lancet 378(9786): 
156-167. 
Appendix 1c: Odds ratios for microvascular outcomes for ADDITION-Leicester and ADDITION-Cambridge* 
 
Routine Care Intensive treatment 
OR (95%-CI) 
ADDITION-Leicester 
Any albuminuria ref 0.49 (0.21-1.15) 
Any retinopathy ref 0.90 (0.45-1.81) 
Neuropathy ref 1.76 (0.91-3.44) 
ADDITION Cambridge 
Any albuminuria ref 1.06 (0.74–1.53) 
Any retinopathy ref 0.77 (0.45–1.32) 
Neuropathy ref 0.55 (0.27–1.12) 
* compare Sandbaek, A., et al. (2014). "Effect of early multifactorial therapy compared with routine care on microvascular outcomes at 5 years in people with 
screen-detected diabetes: a randomized controlled trial: the ADDITION-Europe Study." Diabetes Care 37(7): 2015-2023. 
 
 Appendix 2: Unit cost (£, 2009/10 UK national level) and utility decrement for diabetes and diabetic complications modelled 
by the UKPDS outcomes model 
  
Year of 
event 
  Subsequent years       
  Fatal Non-fatal   Ref. 
Utility 
decrement  
Ref. 
Type 2 diabetes - 494.5 494.5 [32] -0.22 [31] 
IHD - 3558.4 1175.2 [32] -0.09 [29] 
MI 2295.6 6861.8 1129.8 [32] -0.055 [29] 
Heart failure 3968.4 3968.4 1391.1 [32] -0.108 [29] 
Stroke 5786.8 4196.9 793.4 [32] -0.164 [29] 
Re-vascular - 4943.1 316.3 [30] -0.059 [30] 
Amputation 13664.2 13664.2 788.7 [32] -0.28 [29] 
Blindness - 1791.7 758.9 [32] -0.074 [29] 
Renal failure 30599.2 30599.2 30599.2 [31] -0.263 [29] 
CVD death 3724.3 - - [30] -   
Costs extracted from the UKPDS study were based on participant hospital records and survey of 3488 UKPDS participants in 1996-97, from which inpatient 
and out-patient costs were predicted and updated to 2009/10 price year; compare Tao et al. [17] 
 
Appendix 3: Exploration of missing data 
810 out of 31968 (32 variables x 999 observations) data were missing (2.5%).  Missing data at follow-up was 10.9% 
(546 of 4995 data, 5 variables x 999 observations).  Fifteen out of 32 baseline and follow-up variables had one or 
more observations missing.  Missing data did not differ between treatment groups for 10 of the 15 variables.  
However, there was a statistically significant difference in the proportion of missing data between groups for 
baseline height (p=0.002), and follow-up measurements of total cholesterol (p=0.012), HDL (p<0.001), systolic blood 
pressure (p<0.001) and HbA1c (p=0.002).  (Missingness in these follow-up parameters will be very highly correlated 
as they were intended to be collected at the same study visit). 
Parameters associated with missing follow-up data on total and HDL cholesterol, SBP and HbA1c included gender, 
age, smoking status and HbA1c at diagnosis, ethnicity, although overall there is a mixed picture, with some likely 
spurious findings without any clinically plausible causation (e.g. a significant association between height and 
probability of HDL measurement being missing). 
Based on the above, it may be reasonable to conclude that the data are not MCAR, but may be MAR.  However, it is 
not (ever) possible to rule out MNAR.  Given the low overall proportion of missing data (2.5% overall, 10.9% at 
follow-up), we conclude that MI is a reasonable approach to imputing missing data, allowing use of data that would 
otherwise be discarded in a complete case analysis. 
STATA output log follows. 
----------------------------------------------------------------------------------------- 
      name:  <unnamed> 
       log:  ExplorationofMissingness.smcl 
  log type:  smcl 
 opened on:  21 Feb 2017, 09:38:57 
 
. import delimited "Unimputed_data.csv" 
(33 vars, 999 obs) 
 
.  
. * change categorical to numeric 
. gen male =0 
 
. replace male = 1 if gender=="M" 
(612 real changes made) 
 
. drop gender 
 
.  
. gen diag_af = 0 
 
. replace diag_af = 1 if diagnosisatrialfib == "Y" 
(0 real changes made) 
 
. drop diagnosisatrialfib 
 
.  
. gen diag_pvd = 0 
 
. replace diag_pvd = 1 if diagnosispvd == "Y" 
(0 real changes made) 
 
. drop diagnosispvd 
 
.  
. misstable summ, gen(M_) 
                                                               Obs<. 
                                                +------------------------------ 
               |                                | Unique 
      Variable |     Obs=.     Obs>.     Obs<.  | values        Min         Max 
  -------------+--------------------------------+------------------------------ 
        weight |         7                 992  |    397       44.9       169.4 
        height |       125                 874  |    317      1.414        1.92 
  diagnosisc~l |        19                 980  |     65        2.2         9.2 
  diagnosishdl |        23                 976  |    154        .52         3.8 
  diagnosiss~p |         3                 996  |    254   90.33334         228 
  diagnosis~1c |        21                 978  |     90        4.1        15.3 
   currentchol |        19                 980  |     65        2.2         9.2 
    currenthdl |        23                 976  |    154        .52         3.8 
  currentsysbp |         3                 996  |    254   90.33334         228 
  currenthba1c |        21                 978  |     90        4.1        15.3 
     fusmoking |        51                 948  |      3          0           2 
     futotchol |       109                 890  |     53        2.1         8.8 
         fuhdl |       138                 861  |    152         .4         3.9 
         fusbp |       124                 875  |    214         93         220 
       fuhba1c |       124                 875  |     63        3.8        13.4 
  ----------------------------------------------------------------------------- 
 
.  
. * descriptive analysis of missing data 
. * by trial group 
. tabulate group M_weight, chi2 
 
           |      (weight>=.) 
     Group |         0          1 |     Total 
-----------+----------------------+---------- 
         1 |       497          4 |       501  
         2 |       495          3 |       498  
-----------+----------------------+---------- 
     Total |       992          7 |       999  
 
          Pearson chi2(1) =   0.1379   Pr = 0.710 
 
. tabulate group M_height, chi2 
 
           |      (height>=.) 
     Group |         0          1 |     Total 
-----------+----------------------+---------- 
         1 |       422         79 |       501  
         2 |       452         46 |       498  
-----------+----------------------+---------- 
     Total |       874        125 |       999  
 
          Pearson chi2(1) =   9.7328   Pr = 0.002 
 
. tabulate group M_diagnosischol, chi2 
 
           |  (diagnosischol>=.) 
     Group |         0          1 |     Total 
-----------+----------------------+---------- 
         1 |       488         13 |       501  
         2 |       492          6 |       498  
-----------+----------------------+---------- 
     Total |       980         19 |       999  
 
          Pearson chi2(1) =   2.5863   Pr = 0.108 
 
. tabulate group M_diagnosishdl, chi2 
 
           |   (diagnosishdl>=.) 
     Group |         0          1 |     Total 
-----------+----------------------+---------- 
         1 |       486         15 |       501  
         2 |       490          8 |       498  
-----------+----------------------+---------- 
     Total |       976         23 |       999  
 
          Pearson chi2(1) =   2.1378   Pr = 0.144 
 
. tabulate group M_diagnosissysbp, chi2 
 
           |  (diagnosissysbp>=.) 
     Group |         0          1 |     Total 
-----------+----------------------+---------- 
         1 |       499          2 |       501  
         2 |       497          1 |       498  
-----------+----------------------+---------- 
     Total |       996          3 |       999  
 
          Pearson chi2(1) =   0.3283   Pr = 0.567 
 
. tabulate group M_diagnosishba1c, chi2 
 
           |  (diagnosishba1c>=.) 
     Group |         0          1 |     Total 
-----------+----------------------+---------- 
         1 |       489         12 |       501  
         2 |       489          9 |       498  
-----------+----------------------+---------- 
     Total |       978         21 |       999  
 
          Pearson chi2(1) =   0.4196   Pr = 0.517 
 
. tabulate group M_currentchol, chi2 
            |   (currentchol>=.) 
     Group |         0          1 |     Total 
-----------+----------------------+---------- 
         1 |       488         13 |       501  
         2 |       492          6 |       498  
-----------+----------------------+---------- 
     Total |       980         19 |       999  
 
          Pearson chi2(1) =   2.5863   Pr = 0.108 
 
. tabulate group M_currenthdl, chi2 
 
           |    (currenthdl>=.) 
     Group |         0          1 |     Total 
-----------+----------------------+---------- 
         1 |       486         15 |       501  
         2 |       490          8 |       498  
-----------+----------------------+---------- 
     Total |       976         23 |       999  
 
          Pearson chi2(1) =   2.1378   Pr = 0.144 
 
. tabulate group M_currentsysbp, chi2 
 
           |   (currentsysbp>=.) 
     Group |         0          1 |     Total 
-----------+----------------------+---------- 
         1 |       499          2 |       501  
         2 |       497          1 |       498  
-----------+----------------------+---------- 
     Total |       996          3 |       999  
 
          Pearson chi2(1) =   0.3283   Pr = 0.567 
 
. tabulate group M_currenthba1c, chi2 
 
           |   (currenthba1c>=.) 
     Group |         0          1 |     Total 
-----------+----------------------+---------- 
         1 |       489         12 |       501  
         2 |       489          9 |       498  
-----------+----------------------+---------- 
     Total |       978         21 |       999  
 
          Pearson chi2(1) =   0.4196   Pr = 0.517 
 
. tabulate group M_fusmoking, chi2 
 
           |    (fusmoking>=.) 
     Group |         0          1 |     Total 
-----------+----------------------+---------- 
         1 |       470         31 |       501  
         2 |       478         20 |       498  
-----------+----------------------+---------- 
     Total |       948         51 |       999  
 
          Pearson chi2(1) =   2.4311   Pr = 0.119 
 
. tabulate group M_futotchol, chi2 
 
           |    (futotchol>=.) 
     Group |         0          1 |     Total 
-----------+----------------------+---------- 
         1 |       434         67 |       501  
         2 |       456         42 |       498  
-----------+----------------------+---------- 
     Total |       890        109 |       999  
 
          Pearson chi2(1) =   6.2688   Pr = 0.012 
 
. tabulate group M_fuhdl, chi2 
 
           |      (fuhdl>=.) 
     Group |         0          1 |     Total 
-----------+----------------------+---------- 
         1 |       409         92 |       501  
         2 |       452         46 |       498  
-----------+----------------------+---------- 
     Total |       861        138 |       999  
 
          Pearson chi2(1) =  17.4720   Pr = 0.000 
 
. tabulate group M_fusbp, chi2 
            |      (fusbp>=.) 
     Group |         0          1 |     Total 
-----------+----------------------+---------- 
         1 |       417         84 |       501  
         2 |       458         40 |       498  
-----------+----------------------+---------- 
     Total |       875        124 |       999  
 
          Pearson chi2(1) =  17.5252   Pr = 0.000 
 
. tabulate group M_fuhba1c, chi2 
 
           |     (fuhba1c>=.) 
     Group |         0          1 |     Total 
-----------+----------------------+---------- 
         1 |       423         78 |       501  
         2 |       452         46 |       498  
-----------+----------------------+---------- 
     Total |       875        124 |       999  
 
          Pearson chi2(1) =   9.2103   Pr = 0.002 
 
.  
. * association between missingness and baseline variables & observed outcomes 
. logit M_fusmoking i.group i.ethnicity i.male age durationofdiabetes weight height i.dia 
> g_af i.diag_pvd i.diagnosissmoking diagnosischol diagnosishdl diagnosissysbp diagnosish 
> ba1c i.currentsmoking currentchol currenthdl currentsysbp currenthba1c preexistingihd p 
> reexistingchf preexistingamp preexistingblind preexistingrenal preexistingstroke preexi 
> stingmi 
 
note: 1.ethnicity != 1 predicts failure perfectly 
      1.ethnicity dropped and 75 obs not used 
 
note: preexistingstroke != 0 predicts failure perfectly 
      preexistingstroke dropped and 18 obs not used 
 
note: preexistingmi != 0 predicts failure perfectly 
      preexistingmi dropped and 43 obs not used 
 
note: 2.ethnicity omitted because of collinearity 
note: 3.ethnicity omitted because of collinearity 
note: durationofdiabetes omitted because of collinearity 
note: 0.diag_af omitted because of collinearity 
note: 0.diag_pvd omitted because of collinearity 
note: 1.currentsmoking omitted because of collinearity 
note: 2.currentsmoking omitted because of collinearity 
note: currentchol omitted because of collinearity 
note: currenthdl omitted because of collinearity 
note: currentsysbp omitted because of collinearity 
note: currenthba1c omitted because of collinearity 
note: preexistingihd omitted because of collinearity 
note: preexistingchf omitted because of collinearity 
note: preexistingamp omitted because of collinearity 
note: preexistingblind omitted because of collinearity 
note: preexistingrenal omitted because of collinearity 
Iteration 0:   log likelihood = -104.67557   
Iteration 1:   log likelihood = -100.22295   
Iteration 2:   log likelihood = -99.016378   
Iteration 3:   log likelihood = -99.012197   
Iteration 4:   log likelihood = -99.012196   
 
Logistic regression                               Number of obs   =        704 
                                                  LR chi2(11)     =      11.33 
                                                  Prob > chi2     =     0.4163 
Log likelihood = -99.012196                       Pseudo R2       =     0.0541 
 
------------------------------------------------------------------------------------ 
       M_fusmoking |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------------+---------------------------------------------------------------- 
           2.group |  -.4369343    .426696    -1.02   0.306    -1.273243    .3993744 
                   | 
         ethnicity | 
                2  |          0  (empty) 
                3  |          0  (empty) 
                   | 
            1.male |   .5959359   .6852547     0.87   0.384    -.7471386     1.93901 
               age |   .0068199   .0327479     0.21   0.835    -.0573648    .0710047 
durationofdiabetes |          0  (omitted) 
            weight |   .0054153   .0146481     0.37   0.712    -.0232945    .0341252 
            height |  -.6735042   3.406297    -0.20   0.843    -7.349724    6.002716 
         0.diag_af |          0  (omitted) 
        0.diag_pvd |          0  (omitted) 
                   | 
  diagnosissmoking | 
                1  |  -.1189077   .5426201    -0.22   0.827    -1.182424    .9446082 
                2  |   .9886518   .5306364     1.86   0.062    -.0513765     2.02868 
                   | 
     diagnosischol |  -.2643285   .1965389    -1.34   0.179    -.6495377    .1208807 
      diagnosishdl |  -.4479791   .7774532    -0.58   0.564    -1.971759    1.075801 
    diagnosissysbp |   .0037443   .0112236     0.33   0.739    -.0182535    .0257422 
    diagnosishba1c |   .0145227   .1199981     0.12   0.904    -.2206692    .2497145 
                   | 
    currentsmoking | 
                1  |          0  (omitted) 
                2  |          0  (omitted) 
                   | 
       currentchol |          0  (omitted) 
        currenthdl |          0  (omitted) 
      currentsysbp |          0  (omitted) 
      currenthba1c |          0  (omitted) 
    preexistingihd |          0  (omitted) 
    preexistingchf |          0  (omitted) 
    preexistingamp |          0  (omitted) 
  preexistingblind |          0  (omitted) 
  preexistingrenal |          0  (omitted) 
 preexistingstroke |          0  (omitted) 
     preexistingmi |          0  (omitted) 
             _cons |  -2.245222   6.202811    -0.36   0.717    -14.40251    9.912064 
------------------------------------------------------------------------------------ 
 
. logit M_futotchol i.group i.ethnicity i.male age durationofdiabetes weight height i.dia 
> g_af i.diag_pvd i.diagnosissmoking diagnosischol diagnosishdl diagnosissysbp diagnosish 
> ba1c i.currentsmoking currentchol currenthdl currentsysbp currenthba1c preexistingihd p 
> reexistingchf preexistingamp preexistingblind preexistingrenal preexistingstroke preexi 
> stingmi 
 
note: 2.ethnicity != 0 predicts failure perfectly 
      2.ethnicity dropped and 11 obs not used 
 
note: durationofdiabetes omitted because of collinearity 
note: 0.diag_af omitted because of collinearity 
note: 0.diag_pvd omitted because of collinearity 
note: 1.currentsmoking omitted because of collinearity 
note: 2.currentsmoking omitted because of collinearity 
note: currentchol omitted because of collinearity 
note: currenthdl omitted because of collinearity 
note: currentsysbp omitted because of collinearity 
note: currenthba1c omitted because of collinearity 
note: preexistingihd omitted because of collinearity 
note: preexistingchf omitted because of collinearity 
note: preexistingamp omitted because of collinearity 
note: preexistingblind omitted because of collinearity 
note: preexistingrenal omitted because of collinearity 
Iteration 0:   log likelihood = -86.740425   
Iteration 1:   log likelihood = -78.864431   
Iteration 2:   log likelihood = -74.632087   
Iteration 3:   log likelihood = -74.577762   
Iteration 4:   log likelihood = -74.577679   
Iteration 5:   log likelihood = -74.577679   
 
Logistic regression                               Number of obs   =        829 
                                                  LR chi2(14)     =      24.33 
                                                  Prob > chi2     =     0.0418 
Log likelihood = -74.577679                       Pseudo R2       =     0.1402 
 
------------------------------------------------------------------------------------ 
       M_futotchol |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------------+---------------------------------------------------------------- 
           2.group |   .6055944   .5283212     1.15   0.252    -.4298962    1.641085 
                   | 
         ethnicity | 
                2  |          0  (empty) 
                3  |   1.855084   1.214619     1.53   0.127    -.5255253    4.235694 
                   | 
            1.male |  -1.774157   .7614911    -2.33   0.020    -3.266652   -.2816621 
               age |   .1278512   .0527805     2.42   0.015     .0244033    .2312991 
durationofdiabetes |          0  (omitted) 
            weight |   .0145182   .0170165     0.85   0.394    -.0188336      .04787 
            height |   4.867089   3.936642     1.24   0.216    -2.848587    12.58277 
         0.diag_af |          0  (omitted) 
        0.diag_pvd |          0  (omitted) 
                   | 
  diagnosissmoking | 
                1  |   1.023356    .681976     1.50   0.133    -.3132925    2.360004 
                2  |   1.884861   .7276166     2.59   0.010     .4587584    3.310963 
                   | 
     diagnosischol |   .1628792   .2125308     0.77   0.443    -.2536736     .579432 
      diagnosishdl |   .4883364   .6982475     0.70   0.484    -.8802036    1.856876 
    diagnosissysbp |   .0143141    .011474     1.25   0.212    -.0081745    .0368027 
    diagnosishba1c |   .1743563   .1285212     1.36   0.175    -.0775407    .4262532 
                   | 
    currentsmoking | 
                1  |          0  (omitted) 
                2  |          0  (omitted) 
                   | 
       currentchol |          0  (omitted) 
        currenthdl |          0  (omitted) 
      currentsysbp |          0  (omitted) 
      currenthba1c |          0  (omitted) 
    preexistingihd |          0  (omitted) 
    preexistingchf |          0  (omitted) 
    preexistingamp |          0  (omitted) 
  preexistingblind |          0  (omitted) 
  preexistingrenal |          0  (omitted) 
 preexistingstroke |   .0475647   .1322037     0.36   0.719    -.2115498    .3066792 
     preexistingmi |   .0004308   .0812079     0.01   0.996    -.1587337    .1595952 
             _cons |  -26.72693   8.207629    -3.26   0.001    -42.81359   -10.64027 
------------------------------------------------------------------------------------ 
 
. logit M_fuhdl i.group i.ethnicity i.male age durationofdiabetes weight height i.diag_af 
>  i.diag_pvd i.diagnosissmoking diagnosischol diagnosishdl diagnosissysbp diagnosishba1c 
>  i.currentsmoking currentchol currenthdl currentsysbp currenthba1c preexistingihd preex 
> istingchf preexistingamp preexistingblind preexistingrenal preexistingstroke preexistin 
> gmi 
 
note: 2.ethnicity != 0 predicts failure perfectly 
      2.ethnicity dropped and 11 obs not used 
 
note: durationofdiabetes omitted because of collinearity 
note: 0.diag_af omitted because of collinearity 
note: 0.diag_pvd omitted because of collinearity 
note: 1.currentsmoking omitted because of collinearity 
note: 2.currentsmoking omitted because of collinearity 
note: currentchol omitted because of collinearity 
note: currenthdl omitted because of collinearity 
note: currentsysbp omitted because of collinearity 
note: currenthba1c omitted because of collinearity 
note: preexistingihd omitted because of collinearity 
note: preexistingchf omitted because of collinearity 
note: preexistingamp omitted because of collinearity 
note: preexistingblind omitted because of collinearity 
note: preexistingrenal omitted because of collinearity 
Iteration 0:   log likelihood = -145.02106   
Iteration 1:   log likelihood = -137.00905   
Iteration 2:   log likelihood =  -135.5593   
Iteration 3:   log likelihood = -135.55551   
Iteration 4:   log likelihood =  -135.5555   
 
Logistic regression                               Number of obs   =        829 
                                                  LR chi2(14)     =      18.93 
                                                  Prob > chi2     =     0.1676 
Log likelihood =  -135.5555                       Pseudo R2       =     0.0653 
 
------------------------------------------------------------------------------------ 
           M_fuhdl |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------------+---------------------------------------------------------------- 
           2.group |  -.5516725   .3616837    -1.53   0.127     -1.26056    .1572144 
                   | 
         ethnicity | 
                2  |          0  (empty) 
                3  |  -.3972339   1.093944    -0.36   0.717    -2.541325    1.746857 
                   | 
            1.male |  -1.301736   .5508324    -2.36   0.018    -2.381348   -.2221248 
               age |   .0173194   .0294563     0.59   0.557    -.0404139    .0750528 
durationofdiabetes |          0  (omitted) 
            weight |   .0046728   .0120955     0.39   0.699     -.019034    .0283795 
            height |   5.619519   2.861427     1.96   0.050     .0112243    11.22781 
         0.diag_af |          0  (omitted) 
        0.diag_pvd |          0  (omitted) 
                   | 
  diagnosissmoking | 
                1  |   .5523239   .4510155     1.22   0.221    -.3316503    1.436298 
                2  |   1.140725   .4933152     2.31   0.021     .1738448    2.107605 
                   | 
     diagnosischol |    -.16806    .160809    -1.05   0.296    -.4832399    .1471199 
      diagnosishdl |   .5487335   .5323884     1.03   0.303    -.4947285    1.592196 
    diagnosissysbp |   .0105278   .0088739     1.19   0.235    -.0068648    .0279203 
    diagnosishba1c |   .0532259   .1014626     0.52   0.600    -.1456373     .252089 
                   | 
    currentsmoking | 
                1  |          0  (omitted) 
                2  |          0  (omitted) 
                   | 
       currentchol |          0  (omitted) 
        currenthdl |          0  (omitted) 
      currentsysbp |          0  (omitted) 
      currenthba1c |          0  (omitted) 
    preexistingihd |          0  (omitted) 
    preexistingchf |          0  (omitted) 
    preexistingamp |          0  (omitted) 
  preexistingblind |          0  (omitted) 
  preexistingrenal |          0  (omitted) 
 preexistingstroke |  -.0110728   .1450093    -0.08   0.939    -.2952859    .2731402 
     preexistingmi |  -.0362379   .0844939    -0.43   0.668    -.2018428    .1293671 
             _cons |  -15.20218   5.366486    -2.83   0.005     -25.7203    -4.68406 
------------------------------------------------------------------------------------ 
 
. logit M_fusbp i.group i.ethnicity i.male age durationofdiabetes weight height i.diag_af 
>  i.diag_pvd i.diagnosissmoking diagnosischol diagnosishdl diagnosissysbp diagnosishba1c 
>  i.currentsmoking currentchol currenthdl currentsysbp currenthba1c preexistingihd preex 
> istingchf preexistingamp preexistingblind preexistingrenal preexistingstroke preexistin 
> gmi 
 
note: 2.ethnicity != 0 predicts failure perfectly 
      2.ethnicity dropped and 11 obs not used 
 
note: preexistingstroke != 0 predicts failure perfectly 
      preexistingstroke dropped and 18 obs not used 
 
note: preexistingmi != 0 predicts failure perfectly 
      preexistingmi dropped and 44 obs not used 
 
note: durationofdiabetes omitted because of collinearity 
note: 0.diag_af omitted because of collinearity 
note: 0.diag_pvd omitted because of collinearity 
note: 1.currentsmoking omitted because of collinearity 
note: 2.currentsmoking omitted because of collinearity 
note: currentchol omitted because of collinearity 
note: currenthdl omitted because of collinearity 
note: currentsysbp omitted because of collinearity 
note: currenthba1c omitted because of collinearity 
note: preexistingihd omitted because of collinearity 
note: preexistingchf omitted because of collinearity 
note: preexistingamp omitted because of collinearity 
note: preexistingblind omitted because of collinearity 
note: preexistingrenal omitted because of collinearity 
Iteration 0:   log likelihood = -81.567845   
Iteration 1:   log likelihood = -68.508296   
Iteration 2:   log likelihood = -60.419285   
Iteration 3:   log likelihood = -60.035641   
Iteration 4:   log likelihood = -60.032374   
Iteration 5:   log likelihood = -60.032374   
 
Logistic regression                               Number of obs   =        767 
                                                  LR chi2(12)     =      43.07 
                                                  Prob > chi2     =     0.0000 
Log likelihood = -60.032374                       Pseudo R2       =     0.2640 
 
------------------------------------------------------------------------------------ 
           M_fusbp |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------------+---------------------------------------------------------------- 
           2.group |  -.9131446    .605406    -1.51   0.131    -2.099719    .2734295 
                   | 
         ethnicity | 
                2  |          0  (empty) 
                3  |   4.315916   .9033088     4.78   0.000     2.545463    6.086368 
                   | 
            1.male |  -.8184545   .7601726    -1.08   0.282    -2.308365    .6714565 
               age |   .0980135   .0456757     2.15   0.032     .0084907    .1875362 
durationofdiabetes |          0  (omitted) 
            weight |  -.0030261    .017827    -0.17   0.865    -.0379664    .0319142 
            height |   1.316118   4.518181     0.29   0.771    -7.539354    10.17159 
         0.diag_af |          0  (omitted) 
        0.diag_pvd |          0  (omitted) 
                   | 
  diagnosissmoking | 
                1  |    .352746   .8390663     0.42   0.674    -1.291794    1.997286 
                2  |   1.800109   .7406252     2.43   0.015       .34851    3.251707 
                   | 
     diagnosischol |    .143628   .2561239     0.56   0.575    -.3583656    .6456216 
      diagnosishdl |   1.000652    .861717     1.16   0.246    -.6882825    2.689586 
    diagnosissysbp |   -.010975   .0163859    -0.67   0.503    -.0430907    .0211407 
    diagnosishba1c |   .3939303   .1562118     2.52   0.012     .0877608    .7000999 
                   | 
    currentsmoking | 
                1  |          0  (omitted) 
                2  |          0  (omitted) 
                   | 
       currentchol |          0  (omitted) 
        currenthdl |          0  (omitted) 
      currentsysbp |          0  (omitted) 
      currenthba1c |          0  (omitted) 
    preexistingihd |          0  (omitted) 
    preexistingchf |          0  (omitted) 
    preexistingamp |          0  (omitted) 
  preexistingblind |          0  (omitted) 
  preexistingrenal |          0  (omitted) 
 preexistingstroke |          0  (omitted) 
     preexistingmi |          0  (omitted) 
             _cons |  -16.07387   8.862739    -1.81   0.070    -33.44452    1.296782 
------------------------------------------------------------------------------------ 
 
. logit M_fuhba1c i.group i.ethnicity i.male age durationofdiabetes weight height i.diag_ 
> af i.diag_pvd i.diagnosissmoking diagnosischol diagnosishdl diagnosissysbp diagnosishba 
> 1c i.currentsmoking currentchol currenthdl currentsysbp currenthba1c preexistingihd pre 
> existingchf preexistingamp preexistingblind preexistingrenal preexistingstroke preexist 
> ingmi 
 
note: 2.ethnicity != 0 predicts failure perfectly 
      2.ethnicity dropped and 11 obs not used 
 
note: preexistingmi != 0 predicts failure perfectly 
      preexistingmi dropped and 47 obs not used 
 
note: durationofdiabetes omitted because of collinearity 
note: 0.diag_af omitted because of collinearity 
note: 0.diag_pvd omitted because of collinearity 
note: 1.currentsmoking omitted because of collinearity 
note: 2.currentsmoking omitted because of collinearity 
note: currentchol omitted because of collinearity 
note: currenthdl omitted because of collinearity 
note: currentsysbp omitted because of collinearity 
note: currenthba1c omitted because of collinearity 
note: preexistingihd omitted because of collinearity 
note: preexistingchf omitted because of collinearity 
note: preexistingamp omitted because of collinearity 
note: preexistingblind omitted because of collinearity 
note: preexistingrenal omitted because of collinearity 
Iteration 0:   log likelihood = -136.75016   
Iteration 1:   log likelihood = -133.02949   
Iteration 2:   log likelihood = -118.99277   
Iteration 3:   log likelihood = -118.70479   
Iteration 4:   log likelihood = -118.70386   
Iteration 5:   log likelihood = -118.70386   
 
Logistic regression                               Number of obs   =        782 
                                                  LR chi2(13)     =      36.09 
                                                  Prob > chi2     =     0.0006 
Log likelihood = -118.70386                       Pseudo R2       =     0.1320 
 
------------------------------------------------------------------------------------ 
         M_fuhba1c |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------------+---------------------------------------------------------------- 
           2.group |  -.0584053   .3870503    -0.15   0.880    -.8170098    .7001993 
                   | 
         ethnicity | 
                2  |          0  (empty) 
                3  |   3.242644   .6263551     5.18   0.000     2.015011    4.470277 
                   | 
            1.male |  -1.271986   .5590786    -2.28   0.023     -2.36776   -.1762125 
               age |   .0834566   .0327163     2.55   0.011     .0193338    .1475794 
durationofdiabetes |          0  (omitted) 
            weight |   .0091622   .0123752     0.74   0.459    -.0150929    .0334172 
            height |    4.75904   3.074451     1.55   0.122    -1.266772    10.78485 
         0.diag_af |          0  (omitted) 
        0.diag_pvd |          0  (omitted) 
                   | 
  diagnosissmoking | 
                1  |   .4008047   .5096235     0.79   0.432    -.5980389    1.399648 
                2  |   1.386312   .5194204     2.67   0.008     .3682664    2.404357 
                   | 
     diagnosischol |   .0333093   .1715088     0.19   0.846    -.3028419    .3694604 
      diagnosishdl |   .5690557   .5785333     0.98   0.325    -.5648486     1.70296 
    diagnosissysbp |   .0113376   .0096713     1.17   0.241    -.0076177     .030293 
    diagnosishba1c |   .1466052   .1065584     1.38   0.169    -.0622454    .3554557 
                   | 
    currentsmoking | 
                1  |          0  (omitted) 
                2  |          0  (omitted) 
                   | 
       currentchol |          0  (omitted) 
        currenthdl |          0  (omitted) 
      currentsysbp |          0  (omitted) 
      currenthba1c |          0  (omitted) 
    preexistingihd |          0  (omitted) 
    preexistingchf |          0  (omitted) 
    preexistingamp |          0  (omitted) 
  preexistingblind |          0  (omitted) 
  preexistingrenal |          0  (omitted) 
 preexistingstroke |   .0277705   .1338047     0.21   0.836    -.2344818    .2900228 
     preexistingmi |          0  (omitted) 
             _cons |  -20.91242   6.064717    -3.45   0.001    -32.79905   -9.025794 
------------------------------------------------------------------------------------ 
 
.  
. log close 
      name:  <unnamed> 
       log:  ExplorationofMissingness.smcl 
  log type:  smcl 
 closed on:  21 Feb 2017, 09:38:58 
 
 
Appendix 5: Resource utilization according to intensive treatment (IT) and routine care (RC) 
 
* number of annual contacts; ¬ number of annual prescriptions 
 Appendix 6: Adjusted means of annual primary costs according to Intensive Treatment and Routine Care in the years 1-5 # 
  
year 1 year 2 year 3 year 4 year 5 overall 
mean  (SE) mean  (SE) mean  (SE) mean  (SE) mean  (SE) mean  (SE) 
Total * 
IT 809.9 (92.1) 836.9 (92) 886.7 (91.9) 992.8 (92) 1005.1 (92.6) 906.3 (82.2) 
RC 688.0 (90.2) 706.9 (90.4) 847.0 (90.3) 871.2 (90.8) 958.3 (91.1) 814.3 (81) 
dif. 122.0 (128.6) 130.0 (128.7) 39.7 (128.9) 121.5 (129.3) 46.8 (129.9) 92.0
a
 (115.4)
b
 
Total ** 
IT 794.2 (81.1) 822.7 (83.9) 867.2 (88.4) 972.8 (99.2) 1001.0 (102.8) 887.9 (80.7) 
RC 693.6 (69.3) 703.8 (70.5) 846.7 (84.7) 869.4 (87.5) 952.1 (96.1) 806.9 (72.3) 
dif. 100.6 - 118.9 - 20.5 - 103.4 - 48.9 - 80.9 - 
Consultations 
(ADDITION) * 
IT 273.1 (28.6) 241.3 (28.6) 275.1 (28.5) 285.0 (28.6) 257.3 (28.9) 266.4 (23.2) 
RC 241.5 (28.4) 232.4 (28.5) 216.6 (28.4) 231.3 (28.7) 264.5 (28.8) 237.2 (23.5) 
dif. 31.6 (40.1) 8.9 (40.2) 58.6 (40.3) 53.7 (40.5) -7.1 (40.8) 29.1
c
 (33.0)
d
 
Medication 
(ADDITION) * 
IT 134.1 (21.3) 180.3 (21.3) 191.3 (21.3) 200.9 (21.3) 204.1 (21.4) 182.1 (19.9) 
RC 92.8 (21.6) 124.5 (21.6) 133.1 (21.6) 133.9 (21.7) 153.6 (21.7) 127.6 (20.4) 
dif. 41.3 (30.3) 55.7 (30.3) 58.2 (30.3) 67.0 (30.4) 50.5 (30.5) 54.6
e
 (28.5)
f
 
Other primary 
care services* 
IT 398.9 (71) 412.0 (70.9) 416.7 (70.9) 503.4 (71) 539.3 (71.4) 454.1 (63.8) 
RC 352.2 (69) 348.6 (69.1) 495.8 (69.1) 505.5 (69.4) 539.7 (69.6) 448.3 (62.3) 
dif. 46.7 (98.7) 63.4 (98.9) -79.0 (99) -2.1 (99.3) -0.3 (99.8) 5.7 (89.1) 
# generalized linear regression models with a main effect for the intervention and for time since diagnosis and an interaction term between intervention and time; 
adjusted for sex and age of diagnosis and baseline HbA1c; accounted for patients being clustered in GP surgeries and observations clustered in patients 
* GLM with Gaussian distribution and identity link; ** GLM Gamma distribution and log-link 
Estimates used for long-term CE-model: a ß total ; b SE total ;  c ß consultation ;  d SE consultation ; e ß medication ;  f SE medication 
General note: due to the complex 3-level structure of the model estimates on single dimensions do not exactly sum up to the total cost ; 
 
 
